Literature DB >> 9308745

Relationship of anti beta2-glycoprotein I and anti prothrombin antibodies to thrombosis and pregnancy loss in patients with antiphospholipid antibodies.

R R Forastiero1, M E Martinuzzo, G S Cerrato, L C Kordich, L O Carreras.   

Abstract

The lupus anticoagulant (LA) and anticardiolipin antibodies (aCL) are clinically relevant because of their association with thrombosis and pregnancy loss. The group of antiphospholipid antibodies (aPL) includes antibodies primarily directed against various phospholipid-binding proteins, mainly beta2-glycoprotein I (beta2GPI) and prothrombin. Some studies suggest that there is an association between the presence of anti beta2GPI antibodies (alphabeta2GPI) of IgG isotype and thrombosis. Therefore, aPL defined according to the plasma protein to which they are directed appear to be more appropriate for the evaluation of their clinical importance. Using home-made ELISAs we evaluated the presence of alphabeta2GPI and antiprothrombin antibodies (anti-II) of both isotypes (IgG and IgM) in a group of 233 patients with LA and/or aCL. Forty-four women had a history of pregnancy loss, 45 patients had a history of venous thrombosis (VT) and 32 of arterial thrombosis (AT). Patients from the autoimmune group (systemic lupus erythematosus and antiphospholipid syndrome) had a higher prevalence of alphabeta2GPI and/or anti-II than those from the miscellaneous group. In the univariate analysis, a significant association was shown between the presence of alphabeta2GPI-IgG (OR 3.2; 95% CI 1.5-6.6) and previous VT, but not AT. Anti-II were related to VT but the multivariate analysis showed that alphabeta2GPI-IgG are the only independent risk factor for VT (OR 3.0; 95% CI 1.3-6.2). The presence of alphabeta2GPI-IgM correlates well with a history of pregnancy loss (OR 2.6; 95% CI 1.1-6.1). The coagulation tests profile showed that the clotting assays were more prolonged in patients having aCL, alphabeta2GPI or anti-II. But a higher prevalence of abnormal results was only found for the dilute Russell viper venom time in patients with VT, as compared to those without thrombosis (94.4% vs. 58.7%, p <0.02). The measurement of alphabeta2GPI of both isotypes could help to identify aPL-positive patients with a higher risk for thrombosis and pregnancy loss, although this association should be confirmed by prospective studies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9308745

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  13 in total

Review 1.  Testing for and clinical significance of anticardiolipin antibodies.

Authors:  S W Reddel; S A Krilis
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

Review 2.  Antiphospholipid syndrome: multiple mechanisms.

Authors:  C G Mackworth-Young
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

3.  Binding properties of antibodies to prothrombin and beta2-glycoprotein I (beta2-GPI) assayed by ELISA and dot blot.

Authors:  R R Forastiero; M E Martinuzzo; L O Carreras
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

4.  Prevalence of antiphospholipid antibodies in Chilean patients with rheumatoid arthritis.

Authors:  Iván Palomo; Carmen Pinochet; Marcelo Alarcón; Rodrigo Sandoval; Jaime Gonzalez; Francisco Monsalves; Ricardo Forastiero
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

Review 5.  Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant.

Authors:  M Empson; M Lassere; J Craig; J Scott
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

6.  Isotype distribution and clinical relevance of anti-beta2-glycoprotein I (beta2-GPI) antibodies: importance of IgA isotype.

Authors:  G Lakos; E Kiss; N Regëczy; P Tarján; P Soltész; M Zeher; E Bodolay; S Szakony; S Sipka; G Szegedi
Journal:  Clin Exp Immunol       Date:  1999-09       Impact factor: 4.330

7.  Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies.

Authors:  Carolyn Neville; Joyce Rauch; Jeannine Kassis; Erika R Chang; Lawrence Joseph; Martine Le Comte; Paul R Fortin
Journal:  Thromb Haemost       Date:  2003-07       Impact factor: 5.249

Review 8.  Novel insights into associations of antibodies against cardiolipin and beta2-glycoprotein I with clinical features of antiphospholipid syndrome.

Authors:  O Shovman; B Gilburd; O Barzilai; P Langevitz; Y Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

Review 9.  Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances.

Authors:  Savino Sciascia; Mary-Carmen Amigo; Dario Roccatello; Munther Khamashta
Journal:  Nat Rev Rheumatol       Date:  2017-08-03       Impact factor: 20.543

10.  Lower Limb Ischemia: Aortoiliac Thrombosis Related to Antiphospholipid Syndrome (APS)-Case Report and Review of the Literature.

Authors:  Arnaldo Toffon; Raffaella Piovesan; Consolato Francesco Minniti; Omar Caruso; Paolo Criscenti; Sabina Villalta; Maurizio Cavallo
Journal:  Case Rep Surg       Date:  2013-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.